Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Aug 27, 2023; 15(8): 1615-1628
Published online Aug 27, 2023. doi: 10.4240/wjgs.v15.i8.1615
Published online Aug 27, 2023. doi: 10.4240/wjgs.v15.i8.1615
Table 1 Donor characteristics
| BC (n = 21) | Non-BC (n = 229) | P value | |
| Age (yr) | 77.5 ± 5.8 | 77.2 ± 5.2 | 0.757 |
| Sex (female), n (%) | 7 (33.3) | 138 (60.3) | 0.017 |
| BMI (kg/m2) | 26.1 ± 5.1 | 27.4 ± 4.7 | 0.366 |
| Obesity (BMI ≥ 30), n (%) | 5 (23.8) | 57 (25.2) | 0.409 |
| ICU stay (h) | 34 ± 24 | 24 ± 24 | 0.964 |
| Cause of death, n (%) | |||
| Cerebrovascular | 14 (66.7) | 183 (79.9) | 0.773 |
| Head trauma | 5 (23.8) | 36 (15.7) | |
| Other | 2 (9.5) | 10 (4.4) | |
| Hypertension, n (%) | 13 (61.9) | 131 (57.2) | 0.677 |
| Diabetes, n (%) | 5 (23.8) | 47 (20.5) | 0.452 |
| Cardiac arrest, n (%) | 4 (19.0) | 13 (5.7) | 0.043 |
| Hemodynamic instability, n (%) | 9 (42.9) | 67 (29.3) | 0.195 |
| Norepinephrine use, n (%) | 15 (71.4) | 163 (71.2) | 0.981 |
| Laboratory values | |||
| Serum glucose (mg/dL) | 158 ± 42 | 174 ± 70 | 0.378 |
| Serum creatinine (mg/dL) | 0.9 ± 0.5 | 0.8 ± 0.4 | 0.148 |
| Serum sodium (mEq/L) | 145 ± 7 | 146 ± 8 | 0.402 |
| AST (IU/L) | 23 ± 17 | 28 ± 19 | 0.191 |
| ALT (IU/L) | 22 ± 19 | 26 ± 22 | 0.444 |
| GGT (IU/L) | 24 ± 49 | 21 ± 35 | 0.447 |
| Platelets/m3 | 134 ± 84 | 172 ± 86 | 0.016 |
| Prothrombin rate (%) | 77 ± 16 | 72 ± 23 | 0.426 |
| Partial thromboplastin time (s) | 30 ± 6 | 30.5 ± 7.3 | 0.495 |
| Steatosis (biopsy findings) , n (%) | |||
| Microsteatosis | 6 (28.6) | 39 (17.0) | 0.509 |
| Mild macrosteatosis | 4 (19.0) | 61 (26.6) | |
| Moderate macrosteatosis | 0 | 8 (3.5) | |
| Cold ischemia time (min) | 442 ± 225 | 429 ± 235 | 0.783 |
| Warm ischemia time (min) | 55 ± 15 | 55 ± 15 | 0.486 |
| Preservation solution, n (%) | |||
| Celsior | 18 (85.7) | 189 (82.5) | 0.496 |
| Belzer | 3 (14.3) | 40 (17.5) |
Table 2 Pre-liver transplantation recipient characteristics
| Variables | BC (n = 21) | Non-BC (n = 229) | P value |
| Age (yr) | 59 ± 10 | 59 ± 12 | 0.767 |
| Sex (female) | 3 (14.3) | 53 (23.1) | 0.264 |
| LT indications, n (%) | |||
| Alcohol | 11 (52.4) | 97 (42.4) | 0.705 |
| HCV | 7 (33.3) | 80 (34.9) | 0.883 |
| HBV | 0 | 27 (11.8) | 0.081 |
| Biliary related | 1 (4.8) | 5 (2.2) | 0.413 |
| Other | 2 (9.5) | 20 (8.7) | 0.244 |
| HCC, n (%) | 7 (43.8) | 70 (30.6) | 0.793 |
| Pre-LT TACE, n (%) | 3 (42.9) | 31 (44.3) | 0.631 |
| MELD | 11 ± 7 | 13 ± 7 | 0.334 |
| MELD-Na | 11 ± 8 | 13 ± 8 | 0.189 |
| D-MELD | 810 ± 526 | 996 ± 510 | 0.360 |
| UNOS status, n (%) | |||
| Home | 19 (90.5) | 212 (93.4) | 0.343 |
| Hospital | 1 (4.8) | 13 (5.7) | |
| ICU | 1 (4.8) | 2 (5.2) | |
| Medical history, n (%) | |||
| Hypertension | 6 (28.6) | 46 (20.1) | 0.254 |
| Diabetes | 6 (28.6) | 44 (19.2) | 0.223 |
| Pre-LT major abdominal operations | 5 (23.8) | 23 (10) | 0.069 |
| Laboratory values, n (%) | |||
| Serum glucose (mg/dL) | 130 ± 56 | 128 ± 63 | 0.801 |
| Serum creatinine (mg/dL) | 1.1 ± 0.8 | 1 ± 0.6 | 0.823 |
| Serum albumin (g/dL) | 3.6 ± 0.6 | 3.4 ± 0.6 | 0.203 |
| AST (IU/L) | 53 ± 42 | 54 ± 56 | 0.836 |
| ALT (IU/L) | 33 (33) | 33 ± 36 | 0.955 |
| GGT (IU/L) | 57 ± 129 | 61 ± 70 | 0.645 |
| Total bilirubin (mg/dL) | 1.1 ± 0.9 | 1.7 ±2 | 0.036 |
| Leukocytes/mm3 | 4483 ± 2819 | 5356 ± 3110 | 0.063 |
| Hemoglobin (g/100 mL) | 12.6 ± 4.4) | 12.3 ± 3.1 | 0.986 |
| Platelets × 103/mm3 | 100.7 ± 75.6 | 94.2 ± 50.2 | 0.496 |
| Prothrombin rate (%) | 70.6 ± 22.2 | 65 ± 18.3 | 0.030 |
| aPTT (s) | 34.9 ± 5.3 | 36.4 ± 8.1 | 0.272 |
Table 3 Perioperative variables and morbidity/mortality
| Variables | BC (n = 21) | Non-BC (n = 229) | P value |
| Biliary reconstruction, n (%) | |||
| Chol-Chol-without T-tube | 16 (76.2) | 212 (86.9) | 0.013 |
| Chol-Chol-with T-tube | 3 (14.3) | 11 (4.8) | |
| RYHJ | 2 (9.5) | 6 (2.6) | |
| Transfusion (units) | |||
| Packed red blood cells | 7 ± 10 | 5 ± 8 | 0.147 |
| Fresh frozen plasma | 9 ± 12 | 10 ± 10 | 0.647 |
| Platelets | 1 ± 1 | 1 ± 3 | 0.100 |
| Initial immunosuppression, n (%) | |||
| Tacrolimus + steroids | 20 (95.2) | 199 (86.9) | 0.231 |
| Cyclosporine + steroids | 1 (4.8) | 30 (9.8) | |
| Early allograft dysfunction | 4 (19.0) | 32 (14.0) | 0.357 |
| Acute renal failure | 5 (23.8) | 54 (13.1) | 0.581 |
| Non-surgical related infections | 6 (28.6) | 30 (13.1) | 0.062 |
| Acute rejection | 6 (28.6) | 54 (23.6) | 0.608 |
| HCV recurrence | 1 (4.8) | 43 (18.8) | 0.085 |
| HCC recurrence | 0 | 9 (3.9) | 0.446 |
| Non-biliary related reoperation | 1 (4.8) | 12 (5.2) | 0.701 |
| Re-transplantation | 0 | 6 (2.8) | 0.643 |
| ICU stay (d) | 4 ± 5 | 4 ± 4 | 0.559 |
| Hospital stay (d) | 15 ± 13 | 12 ± 10 | 0.326 |
| Patient follow-up (mo) | 46 ± 56 | 72 ± 95 | 0.099 |
| Overall mortality rate, n (%) | 6 (28.6) | 89 (38.9) | 0.352 |
| Causes of death, n (%) | |||
| Cardiovascular disease | 1 (4.8) | 20 (8.7) | 0.041 |
| Infections | 4 (19.0) | 12 (5.2) | |
| Malignancies | 1 (4.8) | 23 (10) | |
| HCV recurrence | 0 | 13 (5.7) | |
| Other | 0 | 21 (9.3) |
Table 4 Univariate and multivariate analysis of predictors of biliary complications
| Univariate analysis | Multivariate analysis | |||
| OR (95%CI) | P value | OR (95%CI) | P value | |
| Donor variables | ||||
| Age (per year) | 1.01 (0.93-1.10) | 0.755 | - | - |
| Sex (female) | 0.33 (0.13-0.85) | 0.021 | 0.27 (0.08-0.90) | 0.033 |
| Obesity (BMI ≥ 30) (Y/N) | 1.26 (0.44-3.64) | 0.661 | - | - |
| Cause of death | ||||
| Cardiovascular vs trauma | 0.55 (0.18-1.62) | 0.143 | - | - |
| Other causes vs trauma | 1.44 (0.24-8.56) | 0.420 | ||
| Cardiac arrest (Y/N) | 3.91 (1.14-13.30) | 0.029 | 7.66 (1.52-38.61) | 0.013 |
| Donor hypertension (Y/N) | 1.21 (0.48-3.04) | 0.677 | - | - |
| Donor diabetes (Y/N) | 1.21 (0.42-3.47) | 0.722 | - | - |
| Platelets/mm3 (per unit) | 1.00 (1.00-1.00) | 0.031 | 1.00 (1.00-1.00) | 0.141 |
| Cold ischemia time (per min) | 0.99 (0.99-1.00) | 0.685 | - | - |
| Recipient variables | ||||
| Age (per year) | 1.01 (0.96-1.06) | 0.620 | - | - |
| Sex (female) | 0.55 (0.15-1.95) | 0.357 | - | - |
| Recipient hypertension (Y/N) | 1.59 (0.58-4.32) | 0.362 | - | - |
| Recipient diabetes (Y/N) | 1.68 (0.61-4.58) | 0.309 | - | - |
| HCC (Y/N) | 1.13 (0.43-2.93) | 0.792 | - | - |
| MELD (per unit) | 0.96 (0.88-1.05) | 0.481 | - | - |
| Total bilirubin (per unit) | 0.63 (0.40-1.02) | 0.160 | - | - |
| Leukocytes/mm3 (per unit) | 1.00 (1.00-1.00) | 0.221 | - | - |
| Prothrombin rate (%) (per unit) | 1.01 (0.99-1.04) | 0.195 | - | - |
| PRBC transfusion (per unit) | 1.02 (0.97-1.06) | 0.332 | - | - |
| Pre-LT major abdominal operations (Y/N) | 2.80 (0.93-8.35) | 0.064 | 3.08 (0.83-11.33) | 0.090 |
| Biliary reconstruction | ||||
| Chol-Chol-with T-tube | 3.61 (0.91-14.27) | 0.486 | - | - |
| RYHJ | 4.41 (0.82-23-67) | 0.342 | ||
Table 5 Diagnosis, management, and outcomes of patients with biliary complications post-liver transplantation with grafts older than 70 years
| Cases | Donor age (yr) | Recipient age (yr) | LT indication | Biliary anastomosis technique | BC type | Diagnosis | Time from LT to BC | PTB dilation (times) | Reoperation: surgical procedure | Current status (causes of death) |
| Donors aged 70-79 yr (13/175, 7.4%) | ||||||||||
| 1 | M (70) | M (49) | Alcohol | Chol-chol-T tube | ABL | US | 7 d | - | - | Deceased (57 m): CV disease |
| 2 | M (73) | M (50) | Alcohol | Chol-chol-T tube | ABS | US, CT scan | 12 m | 1 | - | Deceased (88 m): tumor |
| 3 | M (76) | M (50) | Alcohol | Chol-chol | ABL | US, CT scan | 10 d | - | Roux-en-Y HJ | Deceased (1 m): BC-infection |
| 4 | M (72) | M (61) | HCV | Roux-en-Y HJ | ABS | US | 1 m | 1 | - | Deceased (3 m): aspergillus |
| 5 | F (70) | M (63) | HCV | Chol-chol | ABL | Drainage | 6 d | - | - | Deceased (1 m): BC-infection |
| 6 | M (70) | M (64) | Alcohol + HCC | Chol-chol | ABS | CT scan | 1 m | - | Roux-en-Y HJ | Alive (119 m) |
| 7 | M (73) | M (67) | HCV | Chol-chol | ABS | US, MRIC | 1 m | 4 | Roux-en-Y HJ | Alive (86 m) |
| 8 | M (75) | M (59) | HCV + HCC | Chol-chol | ABS | US, MRIC | 12 m | 4 | - | Alive (65 m) |
| 9 | F (73) | F (37) | Policystic disease | Chol-chol-T tube | ABL | Drainage | 8 d | - | Primary suture | Alive (55 m) |
| 10 | F (79) | M (69) | Cryptogenic | Chol-chol | ABS | US, MRIC | 32 m | - | Roux-en-Y HJ | Alive (46 m) |
| 11 | F (73) | M (57) | HCV + HCC | Chol-chol | ABL | Drainage | 10 d | - | - | Alive (44 m) |
| 12 | M (79) | M (63) | HCV + HCC | Chol-chol | ABL | Drainage, CT scan | 6 d | - | Primary suture | Alive (21 m) |
| 13 | M (75) | M (55) | HCV + HCC | Chol-chol | ABS | MRIC | 13 m | - | Roux-en-Y HJ | Alive (19 m) |
| Donors ≥ 80 yr (8/75, 10.7%) | ||||||||||
| 14 | M (84) | M (52) | Alcohol | Chol-chol | ABS | CT scan | 11 m | - | Roux-en-Y HJ | Alive (249 m) |
| 15 | M (85) | M (71) | Alcohol + HCC | Chol-chol | ABS | CT scan | 13 m | - | - | Alive (126 m) |
| 16 | M (89) | M (58) | Autoimmune | Chol-chol | NABS | MRIC | 21 m | - | - | Alive (52 m) |
| 17 | M (80) | M (54) | Alcohol | Chol-chol | ABS | MRIC | 5 m | 2 | Roux-en-Y HJ | Alive (48 m) |
| 18 | F (81) | F (54) | NASH | Chol-chol | ABS | MRIC | 38 m | 6 | - | Alive (45 m) |
| 19 | F (83) | M (61) | Alcohol + HCC | Chol-chol | ABS | MRIC | 16 m | 2 | Roux-en-Y HJ | Alive (39 m) |
| 20 | F (85) | M (59) | NASH | Chol-chol | ABS | CT scan, MRIC | 3 m | 3 | Roux-en-Y HJ | Alive (39 m) |
| 21 | M (84) | M (67) | SBC | Roux-en-Y HJ | ABL | Drainage, CT scan | 8 d | - | Several procedures | Deceased (2 M): BC-infection |
- Citation: Jimenez-Romero C, Justo-Alonso I, del Pozo-Elso P, Marcacuzco-Quinto A, Martín-Arriscado-Arroba C, Manrique-Municio A, Calvo-Pulido J, García-Sesma A, San Román R, Caso-Maestro O. Post-transplant biliary complications using liver grafts from deceased donors older than 70 years: Retrospective case-control study. World J Gastrointest Surg 2023; 15(8): 1615-1628
- URL: https://www.wjgnet.com/1948-9366/full/v15/i8/1615.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i8.1615
